Cardlytics Inc
$ 3.65
3.69%
07 Aug - close price
- Market Cap 21,493,800 USD
- Current Price $ 3.65
- High / Low $ 3.71 / 3.49
- Stock P/E N/A
- Book Value -2.76
- EPS -20.36
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -4.98 %
- 52 Week High 32.80
- 52 Week Low 3.49
About
Cardlytics, Inc. operates an advertising platform within financial institutions' digital channels including online, mobile, email, and various real-time notifications in the United States and the United Kingdom. The company is headquartered in Atlanta, Georgia.
Analyst Target Price
$7.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-07 | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-03-12 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-03-14 | 2023-11-08 |
| Reported EPS | -1.5 | -1.1 | 0.03 | -1.36 | -1.3 | -2.1 | -0.31 | -1.5 | -1.5 | -0.9 | 0.14 | 0.1 |
| Estimated EPS | -1.35 | -2.13 | -0.2767 | -0.33 | -1.62 | -2.67 | -0.52 | -2.67 | -1.97 | -1.1 | 0.12 | -0.1 |
| Surprise | -0.15 | 1.03 | 0.3067 | -1.03 | 0.32 | 0.57 | 0.21 | 1.17 | 0.47 | 0.2 | 0.02 | 0.2 |
| Surprise Percentage | -11.1111% | 48.3568% | 110.8421% | -312.1212% | 19.7531% | 21.3483% | 40.3846% | 43.8202% | 23.8579% | 18.1818% | 16.6667% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDLX
2026-08-06 13:10:54
Cardlytics, Inc. reported its financial results for the second quarter and six months ended June 30, 2026. The company experienced a decrease in sales and an increase in net loss for the second quarter compared to the previous year. For the six-month period, sales also declined, but the net loss slightly improved year-over-year.
2026-08-06 13:10:54
Cardlytics (NASDAQ: CDLX) reported a significant decline in Q2 2026 revenue to $36.9 million from $58.0 million a year prior, primarily due to a U.S. financial-institution partner exiting its platform and a decrease in Monthly Qualified Users (MQUs). The company posted a total net loss of $14.9 million but achieved a positive Adjusted EBITDA of $1.7 million. Cardlytics completed the sale of its Bridg business, generating a $13.9 million gain, and reduced its revolving credit facility borrowings to $15.0 million.
2026-08-06 07:50:27
The article discusses CDLX's valuation, highlighting that it appears 77.0% undervalued based on GuruFocus's GF Value™ metric, despite facing challenging future prospects. This suggests a potential disconnect between the company's current market price and its intrinsic value as calculated by GuruFocus.
2026-08-05 19:50:27
Cardlytics (NASDAQ: CDLX) reported a net loss of $14.9 million in Q2 2026, with revenue decreasing 36% year-over-year to $36.9 million. The company's Monthly Qualified Users (MQUs) also fell by 17% to 185.4 million, compared to 224.5 million in Q2 2025. Despite these declines, the CEO and CFO highlighted strong operational performance and execution, emphasizing improved margins and new advertiser relationships.
2026-08-03 20:07:00
Cardlytics, Inc. announced an inducement grant of 50,000 restricted stock units to its newly appointed Chief Legal Officer, Chris Cheng, on August 3, 2026. This grant was made under the Cardlytics, Inc. 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over 24 months, subject to continuous service. Cardlytics is a purchase intelligence platform leveraging transaction data for brands and consumers.
2026-08-03 19:44:34
Cardlytics, Inc. announced an inducement grant of 50,000 restricted stock units (RSUs) to its new Chief Legal Officer, Chris Cheng. These RSUs will vest over 24 months, with half vesting on September 1, 2027, and the remainder vesting quarterly over the subsequent 12 months, contingent on continuous employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's 2022 Inducement Plan.
